Consolidation With Hyper-CVAD or VP Plus Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Controlled Trial.
Xiaoyan Zheng, Ruimin Liu, Juan Ren, Huachao Zhu, Pengcheng He, Xiaoning Wang
Clin Lymphoma Myeloma Leuk S2152-2650(26)04007-3
摘要
摘要
BACKGROUND: For Ph+ acute lymphoblastic leukemia (ALL) patients achieving complete molecular response (CMR) pre-transplantation is critical, particularly for those ineligible for bispecific antibodies or CAR-T therapy. OBJECTIVE: To compare the efficacy of 2-4 cycles of VP versus Hyper-CVAD with dasatinib as consolidation therapy in Ph+ ALL. METHODS: This single-center, randomized controlled trial (NCT05026229) enrolled patients aged ≥ 18 years with de novo Ph+ ALL. After 1 cycle of VP (vincristine plus prednisone) plus dasatinib induction, patients were randomized to VP (Arm A) or Hyper-CVAD Part B (high-dose methotrexate and high-dose cytarabine, Arm B) consolidation. Primary endpoint was CMR after cycle 4. Secondary endpoints included CMR rate after cycle 2, CIR, PFS, OS and safety. RESULTS: 31 patients were enrolled before early termination due to excess relapse in the Arm A. For Arm A and Arm B, after cycle 2, CMR rates were 5.6% and 53.8%, and after cycle 4, CMR rates were 5.6% and 69.2%, respectively. With a median follow-up of 40 months, 3-year OS and PFS of Arm A and Arm B were 68.2% versus 57.1% (P = .16), and 31.8% versus 54.8%, respectively (P = .022). CONCLUSION: In Ph+ ALL patients ineligible for cellular immunotherapy, Hyper-CVAD demonstrated superior CMR rates, lower relapse risk, and significantly improved PFS compared with VP, despite no OS difference. The VP arm was terminated early due to high relapse rates, suggesting VP is not recommended as a preferred strategy in this population.
KM 提取结果
0 个 Figure · 0 个 KM 面板